BCAX vs CE · $1.51B cap vs rev $10.28B
Bicara Therapeutics Inc. Common Stock (BCAX) versus Celanese Corporation (CE) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
Celanese Corporation (CE) is a chemicals company listed on US.
BCAX does not have a complete income-statement cache yet.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
BCAX currently screens at market cap $1.51B. CE currently screens at market cap $5.92B.
Not investment advice. Open the BCAX and CE stock pages for the full models.
Not investment advice.